U.S. Companion Animal Infectious Disease Diagnostics Market (2025 - 2033)

U.S. Companion Animal Infectious Disease Diagnostics Market Summary

The U.S. companion animal infectious disease diagnostics market size was estimated at USD 380.6 million in 2024 and is projected to reach USD 635.3 million by 2033, growing at a CAGR of 6.02% from 2025 to 2033. The market growth is fueled by factors such as the rising incidence of infectious diseases, the growing integration of advanced technologies, increasing regulatory approvals for companion animal diagnostic devices, and expanding public-private partnerships in the country.

In the U.S. companion‑animal diagnostics space, innovation is rapidly accelerating by combining advanced technologies and integrative research models. Leading experts in veterinary diagnostics emphasize that artificial intelligence (AI) plays an increasingly central role in transforming everything from bloodwork and urinalysis to imaging platforms and medical record systems.

AI‑powered analyzers such as Zoetis’s Vetscan OptiCell and Imagyst enable faster, more accurate identification of blood cell abnormalities and pathological changes during routine clinic workflows. These systems reduce variability and lighten the workload on veterinary staff while delivering real‑time support for diagnostic decisions. In imaging, machine‑learning models trained on millions of x‑ray and ultrasound images can detect subtle patterns in canine and feline scans, offering near-human-expert diagnostic performance and much quicker turnaround times. AI integration into record‑keeping, scheduling, SOAP‑note automation, and trend‑analysis tools is also streamlining practice management, improving consistency, and freeing veterinarians to focus on patient care and client communication.

At the same time, One Health research initiatives, such as the May 2025 collaboration between Texas A&M and the University of Georgia on Chagas disease in dogs, are reshaping diagnostic priorities by tackling zoonotic infections within a combined animal/human health frame. Backed by over USD 4 million in recent funding, these researchers are developing sensitive diagnostic panels (DNA‑based and serologic biomarkers), staging protocols, and modified therapeutic regimens to manage Trypanosoma cruzi infection in canine cohorts at high risk in southern U.S. settings. By monitoring privately owned pets and working dogs, researchers are gathering clinical and ecological data to capture disease progression, cardiac impact, and exposure routes, feeding directly into improved diagnostics and early intervention strategies. The One Health approach ensures that advances in canine diagnostics and treatment protocols can directly inform human health applications in endemic regions.

Other converging trends fueling growth in companion diagnostics include the increasing complexity of pet care (pet aging, comorbidities), workforce constraints in the veterinary sector, and rising demand for rapid and trustworthy diagnostic results. With connectivity and telemedicine tools, clinics can leverage cloud‑based AI platforms, remote interpretation services, and decision‑support systems to make smarter clinical choices more efficiently.

To conclude, these developments, like AI‑enabled diagnostic technologies delivering heightened speed and accuracy, combined with integrative One Health research collaborations, are propelling the companion‑animal diagnostics industry forward. They enable veterinarians to detect disease earlier, personalize treatment protocols, optimize clinic operations, and align animal health efforts with broader public health goals. Innovations such as hematology analyzers, imaging AI, and disease diagnostic pipelines exemplify how science, clinical practice, and cross‑disciplinary collaboration drive a new era of precision veterinary medicine in the U.S.

Case Study: Public-Private Partnership for One Health

The Los Angeles County Department of Public Health launched the Healthy Pets Healthy Families (HPHF) initiative in 2011 to align pet and human health through a One Health framework. It brought together public and private stakeholders to address shared health issues using data-driven strategies.

HPHF demonstrated how public-private partnerships using One Health principles can bridge gaps between veterinary and human healthcare. The scalable, evidence-based model fosters long-term community and inter-agency resilience.

Market Concentration & Characteristics

In the U.S., innovation is rapidly rising, driven by technologies like next-generation sequencing (NGS). The USDA's NAHLN symposium at Michigan State University, involving 49 labs, reflects growing national momentum to integrate NGS for broad, unbiased pathogen detection, including novel and emerging threats. Alongside this, real-time and multiplex PCR tools are expanding point-of-care capabilities-enabling faster, more affordable, and highly precise diagnostics, and pushing the boundaries of traditional veterinary testing workflows.

In the market, M&A activity remains moderate to high, with firms strategically acquiring diagnostic technology developers, telemedicine platforms, and laboratory service providers. These deals are often aimed at enhancing R&D capacity, expanding distribution channels, and integrating advanced diagnostics into unified care models. The trend reflects companies’ efforts to stay competitive through scale and innovation, particularly in molecular and point-of-care testing. Overall, consolidation is fostering broader access to cutting-edge diagnostic solutions and strengthening infrastructure across veterinary care networks.

Regulations play a pivotal role in shaping the U.S. companion animal infectious disease diagnostics market by ensuring product safety, accuracy, and trust. While agencies like the USDA enforce high standards, recent legal developments-such as the March 2025 dismissal of a consumer lawsuit against Idexx over veterinary diagnostic service pricing-highlight growing scrutiny around cost transparency and market practices. This could drive demand for more affordable, efficient diagnostics and encourage innovation that aligns with regulatory compliance and consumer expectations. More apparent oversight may boost adoption of reliable infectious disease tools while pressuring companies to deliver value-driven solutions.

In the U.S. companion animal infectious disease diagnostics market, product substitution is moderate, with traditional methods like culture, serology, and microscopy still in use, especially in smaller or resource-limited clinics. However, these alternatives often yield slower, less sensitive results than PCR-based diagnostics, which are increasingly preferred for speed and accuracy. The growing emphasis on early, precise detection in U.S. veterinary care steadily reduces reliance on conventional substitutes.

Driven by growing demand, diagnostic companies expand their U.S. footprint through partnerships, exhibitions, and localized strategies to showcase advanced technologies tailored to regional clinical needs. For example, global firms like Anbio Biotechnology actively promote rapid molecular diagnostics in U.S. markets, signaling greater accessibility of innovative tools. These efforts are expected to enhance the availability of companion animal infectious disease diagnostics, particularly in underserved areas, while easing supply chain pressures and accelerating the adoption of high-precision testing solutions.

Product Insight

The consumables, reagents, and kits segment dominated the market with a revenue share of 64.4% in 2024, driven by its recurring use across veterinary clinics, diagnostic labs, and point-of-care settings. The segment is also expected to grow fastest over the forecast period. Unlike instruments, which are largely one-time investments, these materials are essential for routine and specialized tests, such as PCR and ELISA-based assays to detect parvovirus, Lyme disease, and feline leukemia.

Rising pet ownership and a growing emphasis on early disease detection have led to more frequent diagnostic screenings, boosting demand for high-performance kits and reagents. U.S. manufacturers are responding with innovations that offer greater sensitivity, speed, and ease of use, particularly in rapid testing formats, ensuring these products remain central to veterinary diagnostic workflows and revenue generation.

Animal Type Insights

The canine segment dominated the market with the highest revenue share in 2024, driven by a high dog population, increased veterinary spending, and growing awareness of canine health risks. In January 2025, a recent study highlighted that household dogs contribute to the spread of antibiotic-resistant Salmonella, emphasizing the need for early and accurate infectious disease diagnostics. This rising public health concern, coupled with strong emotional bonds between owners and pets, is fuelling demand for advanced diagnostic tools that ensure timely detection and management of zoonotic and canine-specific infections.

The feline segment is expected to exhibit the fastest growth rate over the forecast period. This growth can be attributed to rising cat ownership and growing attention to feline health. Additionally, new research initiatives such as the EveryCat Health Foundation’s March 2025 partnership with Murdoch University are deepening the understanding of feline diseases through advanced diagnostics and genomic research. These efforts enhance early detection and disease management, increase veterinary visits, and drive demand for specialized feline diagnostic tools.

Technology Insight

The immunodiagnostics segment dominated the market and accounted for a revenue share of 49.87% in 2024. This segment, consisting of lateral flow assays (LFAs), ELISA, ad others is primarily driven by its high sensitivity, quick results, and widespread use in veterinary clinics. These technologies are routinely used to detect infectious diseases such as parvovirus in dogs and FeLV in cats. Their cost-effectiveness and ease of use make them essential tools for early diagnosis and high-volume screening, reinforcing their central role in companion animal diagnostics.

The molecular diagnostics segment is expected to grow at the fastest CAGR in the U.S. over the forecast period, fueled by rising demand for rapid and accurate detection of infectious diseases in companion animals. Techniques such as real-time PCR, microarray, and NGS enable early identification of pathogens like canine parvovirus and feline herpesvirus, even in asymptomatic cases, supporting timely intervention and targeted treatment. Contributing to this growth, companies like Alveo Technologies are forming strategic partnerships-such as in February 2025 with Royal GD-to expand access to rapid molecular diagnostics at the point of need. These innovations enhance field-level testing capabilities and align with U.S. efforts to reduce antibiotic misuse through precision diagnostics.

Infection Type Insights

The bacterial infection segment led the U.S. companion animal disease diagnostics market with over 40.56% revenue share in 2024, driven by the high prevalence of infections such as Lyme disease, leptospirosis, and kennel cough in dogs, and feline chlamydiosis in cats. These diseases require early and accurate diagnosis to prevent severe health outcomes. A 2025 study published by medRxiv highlights the widespread detection of Bordetella bronchiseptica and co-infecting bacterial agents across the country, reinforcing the segment’s dominance. The need for multiplex PCR, culture, and serological tests further boosts demand for bacterial diagnostic kits and consumables.

The viral infection segment is projected to grow at the fastest rate of over 6.45% during the forecast period, driven by the rising incidence of highly transmissible viral diseases in companion animals. Infections such as canine distemper, parvovirus, feline leukemia, and canine/feline influenza are becoming increasingly prevalent. Recently, in May 2025, reports of growing feline avian influenza cases across multiple U.S. states highlight the growing concern and the need for robust diagnostic measures. The nonspecific clinical presentation of these viruses makes diagnostic tools indispensable for timely detection, fuelling demand for advanced testing solutions.

End Use Insight

The veterinary hospitals and clinics segment accounted for the largest revenue share of 45.04% in the U.S. companion animal infectious disease diagnostics market in 2024. These facilities serve as the primary access point for diagnostic testing, with veterinarians playing a pivotal role in identifying and managing contagious diseases through timely testing and intervention. Their clinical expertise and adoption of advanced diagnostic tools such as multiplex PCR and point-of-care tests influence test volumes and drive market demand. The growing professionalization of U.S. veterinary practices, emphasis on preventive care, and integration of diagnostics into bundled wellness plans have further boosted uptake. Moreover, veterinarians' efforts to educate pet owners on the risks of infectious diseases and the importance of early detection continue to enhance compliance and ensure recurring diagnostic revenues.

The other segment is expected to register the fastest CAGR in the U.S. companion animal infectious disease diagnostics market over the forecast period. This comprises research institutes and academic laboratories. Research institutions are instrumental in advancing diagnostic innovation through research on disease pathogenesis, biomarker identification, and emerging infectious threats. Their work supports developing and validating novel diagnostic assays, including molecular and serological techniques. Moreover, collaborations between research bodies and diagnostic companies facilitate technology transfer, speeding up the adoption of cutting-edge tools in clinical settings and contributing to the broader market's evolution.

Key U.S. Companion Animal Infectious Disease Diagnostics Company Insights

The U.S. companion animal infectious disease diagnostics market is evolving rapidly, shaped by stringent regulatory standards that promote product reliability while increasing pressure for cost transparency and value-driven solutions. Innovation is accelerating, with advanced technologies like multiplex PCR and NGS enhancing diagnostic speed, accuracy, and point-of-care capabilities.

While traditional diagnostic substitutes still exist, especially in resource-limited settings, their usage is declining in favor of more precise molecular tools. Growing regional expansion efforts are improving access to advanced diagnostics across underserved areas. Meanwhile, steady M&A activity fosters integrated, tech-enabled service models that align with emerging clinical and consumer demands.

Recent Developments

• In June 2025, Zoetis launched a new in‑clinic cortisol test named "The Catalyst Cortisol Test” on its Vetscan platform, delivering reliable results in under an hour. This rapid, point-of-care solution enables quicker decision-making and more timely management of adrenal disorders in dogs and cats

• In February 2025, MiDOG Animal Diagnostics partnered with Exotic Vet Support to broaden its reach into Australia, enabling veterinarians to access its advanced NGS-based microbiome testing for bacterial, fungal, and antimicrobial resistance analysis. This collaboration significantly enhances diagnostic capabilities across species-from companion animals to exotics-offering faster, more accurate results and reducing reliance on traditional culture methods

• In February 2025, MiDOG Animal Diagnostics conducted a webinar titled "Reptile Infectious Diseases in Clinical Practice," which featured experts reviewing NGS-based diagnostics for bacterial, fungal, and viral pathogens in reptiles. The session explored advanced diagnostic techniques, case studies, and real-world applications to improve reptile health care.

U.S. Companion Animal Infectious Disease Diagnostics Market